Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 1, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of April 30, 2018:
- Issued Share Capital: 5,373,908,594 ordinary shares of 25 pence each.
- Treasury Shares: 414,605,950 ordinary shares held in Treasury.
- Total Voting Rights: 4,959,302,644.
Material Changes
The filing text does not provide comparative data or discuss material changes versus prior periods regarding financial performance or capital structure.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under UK disclosure rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,959,302,644) against the latest share register to determine notification thresholds.
- Confirm the number of shares held in Treasury (414,605,950) to ensure accurate calculation of outstanding voting shares.
- Note that this filing does not contain financial results; refer to the Company's Form 20-F or interim reports for financial metrics.